Floatz logo

arx788

HER2 Mutation-Related Tumors

Ambrx, Inc.Phase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

927 Active assets in the HER2 Mutation-Related Tumors cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Inno-206
The First Affiliated Hospital of Soochow University
Phase 2/3BB
DINITROGEN MONOXIDE
Medical College of Wisconsin
Phase 4BB
Glycopyrrolate
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

arx788 is also rated in:

HER2 positive breast carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →
HER2 Amplified Solid TumorsDormant
CCC
Indicative ·
53 / 100
View asset →
angiosarcomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →